DTIL
Precision BioSciences, Inc. NASDAQ Listed Mar 28, 2019$7.47
Mkt Cap $95.8M
52w Low $3.53
74.5% of range
52w High $8.82
50d MA $6.27
200d MA $5.32
P/E (TTM)
-2.0x
EV/EBITDA
0.6x
P/B
1.0x
Debt/Equity
0.3x
ROE
-49.6%
P/FCF
-0.8x
RSI (14)
—
ATR (14)
—
Beta
1.09
50d MA
$6.27
200d MA
$5.32
Avg Volume
270.4K
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
302 East Pettigrew Street · Durham, NC 27701 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | BMO | -0.21 | 0.36 | +271.4% | 5.67 | +1.8% | +0.0% | +0.0% | +11.1% | +22.2% | +24.0% | — |
| Nov 3, 2025 | BMO | -0.31 | -1.84 | -493.5% | 7.36 | -1.5% | -9.1% | -9.1% | -10.1% | -12.5% | -16.6% | — |
| Aug 7, 2025 | BMO | -0.09 | -2.13 | -2266.7% | 4.57 | -0.9% | -4.2% | -4.2% | -4.8% | -4.2% | +2.6% | — |
| May 15, 2025 | BMO | -0.43 | -2.21 | -414.0% | 4.55 | +2.0% | +3.5% | +3.5% | +3.1% | +7.3% | +2.2% | — |
| Mar 26, 2025 | BMO | -2.09 | -3.20 | -53.1% | 4.53 | +2.9% | +0.2% | +0.2% | +3.8% | +5.3% | -0.9% | — |
| Nov 4, 2024 | BMO | -0.79 | -2.83 | -258.2% | 8.29 | -1.6% | +2.1% | +2.1% | +1.3% | +1.6% | +1.1% | — |
| Aug 1, 2024 | BMO | -0.77 | 3.46 | +549.4% | 9.57 | +0.6% | -2.6% | -2.6% | -6.9% | -9.1% | -10.2% | — |
| May 13, 2024 | BMO | -0.45 | -0.35 | +22.2% | 11.50 | +4.3% | +1.0% | +1.0% | +5.1% | +4.2% | +7.8% | — |
| Mar 27, 2024 | BMO | 3.00 | -3.35 | -211.7% | 12.98 | +2.0% | +4.5% | +4.5% | +18.4% | +9.4% | +19.0% | — |
| Nov 7, 2023 | BMO | -5.71 | -3.00 | +47.5% | 11.70 | +2.6% | +0.8% | +0.8% | +1.0% | -2.8% | -12.1% | — |
| Aug 4, 2023 | BMO | -6.91 | -3.00 | +56.6% | 16.80 | +1.8% | -5.2% | -5.2% | -5.9% | -3.6% | -3.6% | — |
| May 9, 2023 | BMO | -6.61 | -6.91 | -4.5% | 25.50 | +0.0% | -2.4% | -2.4% | -11.8% | -12.2% | -10.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.88 | $4.85 | -0.6% | -4.7% | -4.9% | -6.1% | +0.2% | +1.8% |
| Mar 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.54 | $4.75 | +4.6% | +3.5% | +5.1% | -1.1% | +3.3% | +3.7% |
| Mar 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.98 | $4.95 | -0.6% | +0.6% | +7.6% | +9.4% | +13.3% | +2.2% |
| Feb 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.15 | $5.35 | +3.9% | +9.7% | +14.4% | +15.1% | +9.3% | +6.2% |
| Jan 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.50 | $6.80 | +51.1% | +26.7% | +27.6% | +19.6% | +16.9% | +4.9% |
| Jan 10 | BMO Capital | Upgrade | Market Perform → Outperform | — | $4.50 | $6.80 | +51.1% | +26.7% | +27.6% | +19.6% | +16.9% | +4.9% |
| May 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.27 | $12.15 | -1.0% | +4.5% | +5.1% | +6.8% | +7.8% | +6.0% |
| May 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.09 | $12.12 | +0.2% | -0.9% | +2.6% | +6.2% | +7.9% | +8.2% |
| Apr 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.87 | $11.79 | -8.4% | -10.6% | -16.7% | -24.3% | -24.8% | -20.5% |
| Mar 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.98 | $13.24 | +2.0% | +4.5% | +18.4% | +9.4% | +19.0% | +10.5% |
| Feb 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.17 | $11.16 | -0.1% | +7.3% | +3.8% | +6.1% | +15.9% | +10.7% |
| Sep 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.30 | $13.20 | +7.3% | +0.0% | +3.4% | +4.9% | -4.1% | -7.3% |
| Aug 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.90 | $17.64 | +10.9% | -0.9% | -13.2% | -9.4% | -15.1% | -14.2% |
| Jul 27 | BTIG | Maintains | Buy → Buy | — | $17.55 | $17.70 | +0.9% | -3.2% | -3.9% | -1.2% | -0.9% | -6.2% |
| Jul 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.55 | $17.70 | +0.9% | -3.2% | -3.9% | -1.2% | -0.9% | -6.2% |
| May 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.20 | $25.50 | +1.2% | -11.9% | -8.7% | -10.7% | -3.6% | -3.0% |
| Mar 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.67 | $26.34 | -1.2% | +1.1% | -0.1% | -2.1% | -6.6% | -4.4% |
| Mar 13 | BMO Capital | Downgrade | Outperform → Market Perform | — | $27.30 | $28.32 | +3.7% | +2.2% | -2.3% | -1.2% | -2.4% | -4.4% |
| Nov 9 | Goldman Sachs | Maintains | Neutral → Neutral | — | $38.10 | $38.40 | +0.8% | +3.9% | +8.7% | +15.7% | +15.0% | +17.3% |
| Nov 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $38.10 | $38.40 | +0.8% | +3.9% | +8.7% | +15.7% | +15.0% | +17.3% |
| Aug 8 | Goldman Sachs | Maintains | Neutral → Neutral | — | $52.20 | $53.10 | +1.7% | -7.5% | -12.1% | -5.2% | -6.3% | +15.5% |
| Jun 17 | BMO Capital | Maintains | Outperform → Outperform | — | $34.50 | $34.80 | +0.9% | +9.6% | +20.9% | +29.6% | +27.0% | +26.1% |
| Jun 8 | William Blair | Downgrade | Outperform → Market Perform | — | $62.70 | $64.80 | +3.3% | -12.9% | -30.6% | -35.4% | -42.1% | -42.1% |
| Mar 15 | Goldman Sachs | Maintains | Neutral → Neutral | — | $106.20 | $112.20 | +5.6% | -16.4% | -14.4% | -4.5% | -5.4% | -13.8% |
| Sep 9 | Stifel | Maintains | Buy → Buy | — | $378.90 | $381.90 | +0.8% | +1.9% | +0.8% | +0.6% | -4.2% | -1.5% |
| Feb 24 | JonesTrading | Maintains | Buy → Buy | — | $323.10 | $333.00 | +3.1% | +6.9% | +3.3% | +11.0% | +19.5% | +14.2% |
| Dec 6 | JP Morgan | Downgrade | Overweight → Neutral | — | — | — | — | — | — | — | — | — |
| Apr 2 | Goldman Sachs | Downgrade | Buy → Neutral | — | $158.10 | $157.50 | -0.4% | +5.1% | -11.6% | +7.6% | +6.1% | +10.1% |
| Mar 11 | H.C. Wainwright | Maintains | Buy → Buy | — | $227.10 | $227.10 | +0.0% | -14.3% | -28.4% | -18.4% | -33.3% | -23.1% |
| Mar 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $215.70 | $243.60 | +12.9% | +5.3% | -9.7% | -24.6% | -14.0% | -29.8% |
| Mar 5 | Stifel Nicolaus | Maintains | Buy → Buy | — | $243.30 | $247.50 | +1.7% | +2.1% | -1.1% | -11.3% | -6.7% | -20.0% |
| Apr 22 | Goldman Sachs | Maintains | Buy → Buy | — | $365.40 | $386.10 | +5.7% | +10.3% | +11.5% | +4.9% | +2.6% | +3.8% |
| Apr 22 | Barclays | Maintains | Overweight → Overweight | — | $365.40 | $386.10 | +5.7% | +10.3% | +11.5% | +4.9% | +2.6% | +3.8% |
| Apr 22 | Jefferies | Maintains | Buy → Buy | — | $365.40 | $386.10 | +5.7% | +10.3% | +11.5% | +4.9% | +2.6% | +3.8% |
| Apr 22 | JP Morgan | Maintains | Overweight → Overweight | — | $365.40 | $386.10 | +5.7% | +10.3% | +11.5% | +4.9% | +2.6% | +3.8% |
No insider trades available.
8-K · 2.02
!! High
Precision BioSciences, Inc. -- 8-K 2.02: Earnings Results
Precision BioSciences reported earnings results via 8-K filing, with complete financial details available in the attached press release exhibit for investors analyzing DTIL/FTRK performance.
May 5
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
DTIL presented Duchenne muscular dystrophy gene therapy data to key opinion leaders, signaling clinical progress that could validate its pipeline and drive future revenue potential.
Mar 17
8-K
Unknown — 8-K Filing
Precision BioSciences (DTIL) executed its 2025 pipeline milestones, suggesting operational competence, but as a clinical-stage biotech with no revenue, investors face binary trial risk before profitability materializes.
Mar 12
8-K · 8.01
!! High
Precision BioSciences, Inc. -- 8-K 8.01: Material Event / Announcement
Precision BioSciences received FDA clearance to proceed with its FUNCTION-DMD Phase 1/2 clinical trial, allowing the company to activate U.S. clinical sites for its gene therapy treatment.
Feb 11
Data updated apr 25, 2026 5:57am
· Source: massive.com